While captopril offers hemodynamic benefits that slow aneurysm expansion by lowering blood pressure, the ability of cabamiquine to inhibit VSMC phenotypic switching via suppressing eEF2 activity offers a more direct approach for disrupting the cellular pathways underlying AAD progression. Here, EEF2 is linked to aneurysm.